Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta.An annual Alberta Health ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

New report shows an increase in HIV cases in Alberta. Experts tell Hiba Kamal-Choufi there should be a holistic approach to HIV care and treatment.

The Executive Director of UNAIDS Winnie Byanyima is calling for accelerated global solidarity to strengthen Madagascar's response to HIV, including preventing new HIV infections and expanding access ...

Leerink has upgraded Gilead Sciences (NASDAQ:GILD) to outperform, citing the growth outlook for its PrEP treatment ...